Updates and Statements

03.27.2026

Pfizer’s HYMPAVZI Receives Positive CHMP Opinion for Once-Weekly Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors

01.08.2026

The Pfizer Foundation Expands Breast Cancer Initiative to Kenya and Ethiopia with $10 Million in Grants

09.19.2025

ACIP COVID-19 Public Statement

09.19.2025

Pfizer-BioNTech Statement to ACIP Meeting 19th September 2025

09.16.2025

Pfizer Reaffirms Safety and Efficacy of COVID-19 Vaccines

09.15.2025

Pfizer Shares Available Analyses of Myocarditis and COVID-19 Vaccines

09.09.2025

Pfizer Upholds Commitment to Transparency and Shares Analysis of COVID-19 Vaccination in Pregnant Women

09.03.2025

Pfizer Responds to Success of Operation Warp Speed and Reaffirms Transparency of COVID Vaccine Data

08.15.2025

Pfizer Provides Update on Phase 3 Inclacumab Study for the Treatment of People with Sickle Cell Disease

06.13.2025

Pfizer Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer

05.28.2025

Pfizer and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season

03.06.2025

Pfizer Announces New Chief Internal Medicine Officer